Concepedia

Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors

James S. Scott, Adrian L. Gill, Linda Godfrey, Sam D. Groombridge, Amanda Rees, John Revill, Paul N. Schofield, Pernilla Sörme, Andrew Stocker, John G. Swales,

Bioorganic & Medicinal Chemistry Letters · 2012 · 12 citations · 5 references

DOIFull text

Open access

Concepts

References

5

Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus

Per Björntorp, G. Holm, Roland Rosmond · Diabetic Medicine · 1999 · 323 citations

, , +17

Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2

Yuri Kotelevtsev, Roger Brown, Stewart Fleming et al. · Journal of Clinical Investigation · 1999 · 284 citations · Full text

, , +17

Discovery of a Potent, Selective, and Orally Bioavailable Acidic 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitor: Discovery of 2-[(3<i>S</i>)-1-[5-(Cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic Acid (AZD4017)

James S. Scott, Suzanne S. Bowker, Joanne deSchoolmeester et al. · Journal of Medicinal Chemistry · 2012 · 62 citations · Full text

, , +15

11β-Hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents

Scott P. Webster, T. David Pallin · Expert Opinion on Therapeutic Patents · 2007 · 39 citations

, , +17

Reduction of acyl glucuronidation in a series of acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors: the discovery of AZD6925

James S. Scott, Peter Barton, Stuart N. L. Bennett et al. · MedChemComm · 2012 · 11 citations

, , +14